Welcome to our dedicated page for Aligos Therapeutics SEC filings (Ticker: ALGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aligos Therapeutics, Inc. (NASDAQ: ALGS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical stage biotechnology issuer focused on liver and viral diseases. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that describe Aligos’ operations, capital structure, and governance.
Aligos files Form 8-K current reports to announce material events such as financial results, annual meeting outcomes, amendments to its certificate of incorporation, and changes to equity incentive plans. For example, the company has reported quarterly financial results and detailed stockholder votes on proposals to increase authorized shares of voting and non-voting common stock, as well as amendments to its 2020 Incentive Award Plan. These filings outline how Aligos manages its share capital and equity-based compensation.
Through its periodic reports, Aligos discusses its status as a clinical stage biotechnology company developing therapeutics for chronic hepatitis B virus infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. Investors can use these filings to understand the company’s pipeline focus, research and development spending, and other aspects of its business model. The filings also confirm that Aligos’ common stock, with a par value of $0.0001 per share, is listed on The Nasdaq Stock Market LLC (Nasdaq Capital Market) under the symbol ALGS.
On Stock Titan, SEC filings for ALGS are complemented by AI-powered summaries that highlight key points from lengthy documents. These tools help readers quickly identify information on topics such as clinical program updates, capital structure changes, and stockholder approvals, while still allowing access to the full-text filings as made available through the EDGAR system.
Aligos Therapeutics (NASDAQ:ALGS) filed a routine Form 4 reporting a new stock-option grant to director Peter Hirth.
The filing shows Mr. Hirth received 5,860 stock options with an exercise price of $7.63 per share on June 25 2025. The options vest 100 % on the earlier of the first anniversary of the grant date or immediately before the company’s 2026 annual meeting, contingent on continued board service. Following the grant, Mr. Hirth beneficially owns 5,860 derivative securities; no non-derivative share transactions were reported.
No sales, purchases of common stock, or other material changes in ownership were disclosed. The transaction appears to be a standard director compensation award and does not, by itself, indicate a material change in Aligos Therapeutics’ financial outlook or governance.
Aligos Therapeutics (NASDAQ: ALGS) submitted a routine Form 4 disclosing a standard equity compensation grant to director Heather Preston. On 06/25/2025, Preston received 5,860 non-qualified stock options with an exercise price of $7.63 per share, matching the prevailing market price. The award vests 100 percent on the earlier of the first anniversary of the grant or immediately before the 2026 annual shareholder meeting, conditional on continued board service. No common shares were purchased or sold, and Preston’s beneficial ownership now reflects only the newly issued derivative securities.
Aligos Therapeutics (NASDAQ: ALGS) filed a routine Form 4 disclosing an insider stock-option grant to director Margarita Chavez.
On June 25 2025, Chavez received an option to purchase 5,860 common shares at an exercise price of $7.63. The option vests 100 % on the earlier of the first anniversary of the grant or immediately prior to the company’s 2026 annual meeting, and expires on June 25 2035. No shares were bought or sold in the open market, and beneficial ownership remains unchanged except for the new option award.
The filing appears to reflect standard board compensation and does not indicate any material change in corporate strategy, financial condition, or insider sentiment.
Aligos Therapeutics (NASDAQ:ALGS) filed a routine Form 4 disclosing an insider grant. On June 25 2025, director Bridget A. Martell was awarded 5,860 stock options with a strike price of $7.63 per share. The options vest 100 % on the earlier of the first anniversary of the grant date or immediately before the 2026 annual shareholder meeting and expire on June 25 2035. After the transaction, Martell beneficially owns 5,860 derivative securities. No open-market purchases or sales of ALGS common stock were reported.
Aligos Therapeutics (Nasdaq:ALGS) filed an 8-K disclosing results of its June 25, 2025 Annual Meeting.
- Authorized share increase: voting common stock rises from 20 million to 100 million; non-voting common stock from 0.8 million to 15.8 million (Item 5.03).
- Equity plan expansion: 2020 Incentive Award Plan enlarged by 1,000,000 shares (Item 5.02).
- All proposals passed with c.~87% support; three Class II directors re-elected and Ernst & Young ratified as auditor (Item 5.07).
- Shares outstanding on record date: 5,314,801.
The amendments give management broad capacity to issue new equity for financing or compensation, but materially raise dilution risk for existing holders. No financial results were reported.